Journal
ANNALS OF ONCOLOGY
Volume 27, Issue 5, Pages 778-787Publisher
ELSEVIER
DOI: 10.1093/annonc/mdw029
Keywords
lymphomas; treatment; novel agents; ibrutinib; idelalisib; venetoclax
Categories
Funding
- Pharmacyclics
- Janssen
- Celgene
- Novartis
- Millenium
- Onyx
- Abbvie
- Roche
- Gilead
- Infinity
Ask authors/readers for more resources
This comprehensive review provides a detailed analysis of the breakthrough agents in the field, with a focus on recent clinical data. We describe agents targeting the B-cell receptor pathway, Bcl-2 inhibitors, emerging epigenetic therapies, new monoclonal antibodies and antibody drug conjugates, selective inhibitors of nuclear export, PD-1 inhibitors and chimeric antigen receptor T cells.The last 5 years have seen significant advances in our understanding of the molecular pathogenesis of B-cell lymphomas. This has led to the emergence of a large number of new therapeutic agents exploiting precise aspects of the tumor cell's signaling pathways, surface antigens or microenvironment. The purpose of this comprehensive review is to provide a detailed analysis of the breakthrough agents in the field, with a focus on recent clinical data. We describe agents targeting the B-cell receptor pathway, Bcl-2 inhibitors, emerging epigenetic therapies, new monoclonal antibodies and antibody drug conjugates, selective inhibitors of nuclear export, agents targeting the programmed cell death axis and chimeric antigen receptor T cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available